NVAX Q4 2021 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$727M-359.8% YoY

Gross Profit

-$727M100.0% margin

Operating Income

-$825M113.6% margin

Net Income

-$846M116.5% margin

EPS (Diluted)

$-11.33

QoQ Revenue Growth

-506.2%

Cash Flow

Operating Cash Flow

-$342M

Free Cash Flow

-$359M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$2.9B

Stockholders' Equity

-$352M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$727M	$280M	-359.8%
Gross Profit	-$727M	$280M	-359.8%
Operating Income	-$825M	-$183M	-351.2%
Net Income	-$846M	-$178M	-376.6%